Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?

Abstract

Background Consensus in timing of radiotherapy is yet to be established in esthesioneuroblastoma (ENB).

Objective This study was aimed to investigate if planned adjuvant radiotherapy improves tumor control after complete margin negative resection of low Hyams' grade (1 or 2) ENB.

Methods A retrospective review of patients with pathologically confirmed negative margin resection of Kadish's stage B or C and Hyams' grade 1 and 2 ENBs was conducted. Seventeen patients meeting the criteria were divided into the following two groups for cohort study: (1) those who underwent planned immediate postoperative adjuvant radiotherapy (IR group) and (2) those who did not (delayed radiotherapy [DR] group).

Results The IR group included nine patients (Kadish's stage B in one and stage C in eight; Hyams' grade 1 in two and grade 2 in seven). Mean follow-up was 140.8 months. Seven patients (78%) had disease progression (DP) at a median of 88 months (four with cervical lymph node metastasis [CLNM], one with distant metastasis, and two with both local recurrence and CLNM). One patient experienced frontal lobe abscess. The DR group included eight patients (Kadish's stage B in six and stage C in two; all Hyams' grade 2). Mean follow-up was 123.3 months. Four (50%) patients who developed DP (all local recurrence) were salvaged with surgery and adjuvant radiotherapy at a median of 37.5 months. There was no statistically significant difference in DP rate (p = 0.23), time to DP (p = 0.26), or the local tumor control rate (p = 0.23).

Conclusion In our limited cohort, immediate postoperative radiotherapy did not demonstrate superiority in tumor control, although risk of radiotherapy toxicity appears low.

Keywords

craniofacial resection - esthesioneuroblastoma - intensity-modulated radiation therapy - olfactory neuroblastoma - surgical treatment

Publikationsverlauf

Eingereicht: 20. August 2019

Angenommen: 14. Februar 2020

Artikel online veröffentlicht:
25. März 2020

• References

• 1 Dias FL, Sa GM, Lima RA. et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129 (11) 1186-1192
• 2 Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123 (03) 433-439
• 3 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37 (03) 1571-1576
• 4 Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990; 100 (11) 1199-1201
• 5 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102 (08) 843-849
• 6 Hyams V. Tumors of the upper respiratory tract and ear. In: VJ Hyams JB, L Michaels, ed. Atlas of Tumor Pathology. Vol. 2. Washington, DC: Armed Forces Institute of Pathology; 1988: 240-248
• 7 Kaur G, Kane AJ, Sughrue ME. et al. The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci 2013; 20 (02) 281-286
• 8 Peacock JG, Harmsen WS, Link MJ. et al. Risk of delayed lymph node metastasis in clinically no esthesioneuroblastoma. J Neurol Surg B Skull Base 2017; 78 (01) 68-74
• 9 Van Gompel JJ, Giannini C, Olsen KD. et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base 2012; 73 (05) 331-336
• 10 Van Gompel JJ, Link MJ, Sheehan JP. et al. Radiosurgery is an effective treatment for recurrent esthesioneuroblastoma: a multicenter study. J Neurol Surg B Skull Base 2014; 75 (06) 409-414
• 11 Benfari G, Fusconi M, Ciofalo A. et al. Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital 2008; 28 (06) 292-297
• 12 Suriano M, De Vincentiis M, Colli A, Benfari G, Mascelli A, Gallo A. Endoscopic treatment of esthesioneuroblastoma: a minimally invasive approach combined with radiation therapy. Otolaryngol Head Neck Surg 2007; 136 (01) 104-107
• 13 Xiong L, Zeng XL, Guo CK, Liu AW, Huang L. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients. BMC Cancer 2017; 17 (01) 254
• 14 Lapierre A, Selmaji I, Samlali H, Brahmi T, Yossi S. [Esthesioneuroblastoma: A single institution's experience and general literature review] (in French). Cancer Radiother 2016; 20 (08) 783-789
• 15 Eich HT, Müller RP, Micke O, Kocher M, Berthold F, Hero B. Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?. Strahlenther Onkol 2005; 181 (06) 378-384
• 16 Polin RS, Sheehan JP, Chenelle AG. et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery 1998; 42 (05) 1029-1037
• 17 McElroy Jr EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998; 42 (05) 1023-1027
• 18 Porter AB, Bernold DM, Giannini C. et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol 2008; 90 (02) 201-204
• 19 Miyamoto RC, Gleich LL, Biddinger PW, Gluckman JL. Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis. Laryngoscope 2000; 110 (08) 1262-1265
• 20 Koch M, Constantinidis J, Dimmler A, Strauss C, Iro H. [Long-term experiences in the therapy of esthesioneuroblastoma] (in German). Laryngorhinootologie 2006; 85 (10) 723-730
• 21 Constantinidis J, Steinhart H, Koch M. et al. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg 2004; 130 (05) 567-574
• 22 Klironomos G, Gonen L, Au K. et al. Endoscopic management of Esthesioneuroblastoma: our experience and review of the literature. J Clin Neurosci 2018; 58: 117-123
• 23 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32 (05) 706-714
• 24 Castelnuovo P, Bignami M, Delù G, Battaglia P, Bignardi M, Dallan I. Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience. Head Neck 2007; 29 (09) 845-850
• 25 Castelnuovo PG, Delù G, Sberze F. et al. Esthesioneuroblastoma: endonasal endoscopic treatment. Skull Base 2006; 16 (01) 25-30
• 26 Folbe A, Herzallah I, Duvvuri U. et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy 2009; 23 (01) 91-94
• 27 Devaiah AK, Larsen C, Tawfik O, O'Boynick P, Hoover LA. Esthesioneuroblastoma: endoscopic nasal and anterior craniotomy resection. Laryngoscope 2003; 113 (12) 2086-2090
• 28 Zanation AM, Ferlito A, Rinaldo A. et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol 2010; 267 (11) 1667-1671
• 29 Loy AH, Reibel JF, Read PW. et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132 (02) 134-138
• 30 Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73 (02) 424-432
• 31 Duprez F, Madani I, Morbée L. et al. IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys 2012; 83 (01) 252-259
• 32 Dagan R, Bryant C, Li Z. et al. Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys 2016; 95 (01) 377-385
• 33 Nakamura N, Zenda S, Tahara M. et al. Proton beam therapy for olfactory neuroblastoma. Radiother Oncol 2017; 122 (03) 368-372
• 34 Lucas Jr JT, Ladra MM, MacDonald SM. et al. Proton therapy for pediatric and adolescent esthesioneuroblastoma. Pediatr Blood Cancer 2015; 62 (09) 1523-1528
• 35 Herr MW, Sethi RK, Meier JC. et al. Esthesioneuroblastoma: an update on the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. J Neurol Surg B Skull Base 2014; 75 (01) 58-64
• 36 Kim HJ, Cho HJ, Kim KS. et al. Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma. J Craniomaxillofac Surg 2008; 36 (01) 47-52
• 37 Gore MR, Zanation AM. Salvage treatment of local recurrence in esthesioneuroblastoma: a meta-analysis. Skull Base 2011; 21 (01) 1-6
• 38 Naples JG, Spiro J, Tessema B, Kuwada C, Kuo CL, Brown SM. Neck recurrence and mortality in esthesioneuroblastoma: Implications for management of the no neck. Laryngoscope 2016; 126 (06) 1373-1379
• 39 Monroe AT, Hinerman RW, Amdur RJ, Morris CG, Mendenhall WM. Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation. Head Neck 2003; 25 (07) 529-534
• 40 Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133 (03) 276-280